Pharmaceutical

Lutetium (lu177) lilotomab satetraxetan by Thor Medical for B-Cell Chronic Lymphocytic Leukemia: Likelihood of Approval

Lutetium (lu177) lilotomab satetraxetan is under clinical development by Thor Medical and currently in Phase II for B-Cell Chronic Lymphocytic Leukemia.

Aug 28, 2023 - 20:00
Lutetium (lu177) lilotomab satetraxetan is under clinical development by Thor Medical and currently in Phase II for B-Cell Chronic Lymphocytic Leukemia.
Read the original article

Tags:

Previous Article

Signal: Allina health will no longer bar indebted patients from care

Next Article

BR-6002 by Boryung Pharmaceutical for Duodenal Ulcer: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Checklists to screen for patients’ social needs aren’t helping

Opinion: Checklists to screen for patients’ social need...

May 23, 2023

STAT+: GOP senator probes drug discount programs at Cleveland Clinic, Bon Secours

STAT+: GOP senator probes drug discount programs at Cle...

Sep 28, 2023

The Biotech Effect

The Biotech Effect

Apr 16, 2023